$DFFN
Diffusion Pharmaceuticals Announces Pre-IND Submission to the FDA of Design for TSC Trials to Treat Acute Respiratory Distress Syndrome in COVID-19
https://t.co/aCfO23iJYQ

#daytrade #daytrading #stocks #stockmarketnews #stockstowatch